Micafungin Hikma

Micafungin, the active ingredient in Micafungin Hikma, is an echinocandin presented as an intravenous formulation for intravenous use. It treats invasive candidiasis and related fungal infections in immunocompromised patients.

GNH USA supplies Micafungin Hikma as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

Micafungin is an echinocandin antifungal used to manage serious Candida infections. - Invasive candidiasis: eradicates bloodstream and deep‑tissue Candida infections. - Esophageal candidiasis: resolves mucosal Candida overgrowth in the esophagus. - Prophylaxis of Candida infections in hematopoietic stem cell transplantation: prevents invasive candidiasis in transplant recipients. - Candida peritonitis: treats intra‑abdominal Candida infections. - Candida bloodstream infections: clears fungemia caused by Candida species.

Micafungin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Fever: transient elevation of body temperature. - Nausea: mild to moderate upset stomach. - Headache: occasional mild headache. - Infusion‑related reactions: flushing, chills, or mild hypotension during administration. - Elevated liver enzymes: transient increase in ALT/AST. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Severe hypersensitivity: anaphylaxis or angioedema. - Hepatotoxicity: significant liver injury with jaundice. - Severe hypotension: marked drop in blood pressure requiring intervention. - Acute renal failure: sudden loss of kidney function. - Stevens‑Johnson syndrome: rare severe skin reaction. - Cytopenias: notable reductions in blood cell counts.

Before using Micafungin, clinicians should consider several safety measures. - Liver function monitoring: assess baseline and periodic ALT/AST levels. - Renal function assessment: evaluate creatinine clearance, especially in patients with pre‑existing kidney disease. - Hypersensitivity screening: avoid in patients with known allergy to echinocandins. - Cardiovascular caution: monitor blood pressure during infusion in patients with heart failure. - Drug interaction review: check concomitant medications that affect hepatic metabolism. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Micafungin can interact with several agents; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Cyclosporine: increased cyclosporine exposure may cause nephrotoxicity. - Tacrolimus: elevated tacrolimus levels can lead to toxicity. - Sirolimus: risk of heightened immunosuppression.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of INR; monitor coagulation. - Oral contraceptives: reduced efficacy possible; advise alternative contraception. - Rifampin: may decrease micafungin concentrations. - Carbamazepine: may lower micafungin exposure. - Fluconazole: additive antifungal effect; monitor for toxicity.